These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11964269)

  • 1. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.
    Chen BJ; Cui X; Liu C; Chao NJ
    Blood; 2002 May; 99(9):3083-8. PubMed ID: 11964269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.
    McIver ZA; Grayson JM; Coe BN; Hill JE; Schamerhorn GA; Ohulchanskyy TY; Linder MK; Davies KS; Weiner RS; Detty MR
    J Immunol; 2016 Sep; 197(5):1631-41. PubMed ID: 27456485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease.
    Goggins TF; Chao N
    Leuk Lymphoma; 2003 Nov; 44(11):1871-9. PubMed ID: 14738138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
    Hartwig UF; Robbers M; Wickenhauser C; Huber C
    Blood; 2002 Apr; 99(8):3041-9. PubMed ID: 11929798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
    Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
    J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.
    Blazar BR; Carroll SF; Vallera DA
    Blood; 1991 Dec; 78(11):3093-102. PubMed ID: 1954395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice.
    Chen Y; Zeng D; Schlegel PG; Fidler J; Chao NJ
    Blood; 2000 Jan; 95(2):705-10. PubMed ID: 10627483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL; Forman J
    J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.
    Guimond M; Balassy A; Barrette M; Brochu S; Perreault C; Roy DC
    Blood; 2002 Jul; 100(2):375-82. PubMed ID: 12091325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
    Annat J; Churaqui E; Dutartre P; Bruley-Rosset M
    Transplantation; 1996 Sep; 62(6):721-9. PubMed ID: 8824467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice.
    Weiss L; Reich S; Slavin S
    Bone Marrow Transplant; 1996 May; 17(5):789-92. PubMed ID: 8733699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination.
    Cavazzana-Calvo M; Stephan JL; Sarnacki S; Chevret S; Fromont C; de Coene C; Le Deist F; Guy-Grand D; Fischer A
    Blood; 1994 Jan; 83(1):288-98. PubMed ID: 8274744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
    Palathumpat V; Dejbakhsh-Jones S; Strober S
    Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.